

Yukiko Kimura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1020505/publications.pdf>

Version: 2024-02-01

49
papers

2,678
citations

304368

22
h-index

243296

44
g-index

52
all docs

52
docs citations

52
times ranked

2062
citing authors

#	ARTICLE	IF	CITATIONS
1	2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: Initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. <i>Arthritis Care and Research</i> , 2011, 63, 465-482.	1.5	658
2	Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2012, 64, 2012-2021.	6.7	259
3	2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications. <i>Arthritis and Rheumatism</i> , 2013, 65, 2499-2512.	6.7	211
4	Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 1001-1010.	1.5	172
5	<i>HLA-DRB1*11</i> and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 15970-15975.	3.3	139
6	Pulmonary Hypertension and Other Potentially Fatal Pulmonary Complications in Systemic Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2013, 65, 745-752.	1.5	126
7	Long-Term Safety and Efficacy of Riloncept in Patients With Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2486-2496.	6.7	109
8	Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for New-Onset Polyarticular Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1063-1072.	1.5	101
9	Enthesitis-related Arthritis Is Associated with Higher Pain Intensity and Poorer Health Status in Comparison with Other Categories of Juvenile Idiopathic Arthritis: The Childhood Arthritis and Rheumatology Research Alliance Registry. <i>Journal of Rheumatology</i> , 2012, 39, 2341-2351.	1.0	80
10	The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months. <i>Pediatric Rheumatology</i> , 2017, 15, 30.	0.9	80
11	Disease-modifying Antirheumatic Drug Use in the Treatment of Juvenile Idiopathic Arthritis: A Cross-sectional Analysis of the CARRA Registry. <i>Journal of Rheumatology</i> , 2012, 39, 1867-1874.	1.0	76
12	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2022, 74, 553-569.	2.9	68
13	Clinically Inactive Disease in a Cohort of Children with New-onset Polyarticular Juvenile Idiopathic Arthritis Treated with Early Aggressive Therapy: Time to Achievement, Total Duration, and Predictors. <i>Journal of Rheumatology</i> , 2014, 41, 1163-1170.	1.0	61
14	The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013. <i>Journal of Rheumatology</i> , 2016, 43, 1755-1762.	1.0	41
15	Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. <i>Pediatric Rheumatology</i> , 2017, 15, 23.	0.9	41
16	The Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. <i>Arthritis and Rheumatology</i> , 2018, 70, 669-678.	2.9	40
17	Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. <i>Arthritis and Rheumatology</i> , 2019, 71, 451-459.	2.9	36
18	Extension Study of Participants from the Trial of Early Aggressive Therapy in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2459-2465.	1.0	35

#	ARTICLE	IF	CITATIONS
19	Adding Canakinumab to the Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Systemic Juvenile Idiopathic Arthritis: Comment on the Article by DeWitt et al. <i>Arthritis Care and Research</i> , 2014, 66, 1430-1431.	1.5	28
20	New Medications Are Needed for Children With Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1945-1951.	2.9	28
21	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2022, 74, 521-537.	1.5	27
22	Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease. <i>Arthritis and Rheumatology</i> , 2018, 70, 1508-1518.	2.9	26
23	Multisite Randomized Clinical Trial Evaluating an Online Self-Management Program for Adolescents With Juvenile Idiopathic Arthritis. <i>Journal of Pediatric Psychology</i> , 2019, 44, 363-374.	1.1	24
24	Adding patient-reported outcomes to a multisite registry to quantify quality of life and experiences of disease and treatment for youth with juvenile idiopathic arthritis. <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, .	0.9	20
25	Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FIrst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST). <i>Clinical Trials</i> , 2018, 15, 268-277.	0.7	19
26	Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. <i>Arthritis and Rheumatology</i> , 2021, 73, 1898-1909.	2.9	19
27	Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial. <i>Pediatric Rheumatology</i> , 2019, 17, 57.	0.9	18
28	Improved Disease Course Associated With Early Initiation of Biologics in Polyarticular Juvenile Idiopathic Arthritis: Trajectory Analysis of a Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans Study. <i>Arthritis and Rheumatology</i> , 2021, 73, 1910-1920.	2.9	18
29	Efficacy and Safety of Tocilizumab for Polyarticular Course Juvenile Idiopathic Arthritis in the Open-Label Two-Year Extension of a Phase III Trial. <i>Arthritis and Rheumatology</i> , 2021, 73, 530-541.	2.9	16
30	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. <i>Arthritis Care and Research</i> , 2022, 74, 505-520.	1.5	15
31	A randomized study of local anesthesia for pain control during intra-articular corticosteroid injection in children with arthritis. <i>Pediatric Rheumatology</i> , 2015, 13, 36.	0.9	11
32	High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy. <i>Arthritis and Rheumatology</i> , 2018, 70, 594-605.	2.9	11
33	2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for Nonpharmacologic Therapies, Medication Monitoring, Immunizations, and Imaging. <i>Arthritis and Rheumatology</i> , 2022, 74, 570-585.	2.9	11
34	Primary Sjögren Syndrome in a Child with a Neuromyelitis Optica Spectrum Disorder. <i>Journal of Rheumatology</i> , 2016, 43, 1260-1261.	1.0	10
35	Pain in children with rheumatic diseases. <i>Current Rheumatology Reports</i> , 2006, 8, 480-488.	2.1	8
36	Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1976-1984.	2.9	8

#	ARTICLE	IF	CITATIONS
37	The burden of systemic juvenile idiopathic arthritis for patients and caregivers: an international survey and retrospective chart review. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 920-928.	0.4	8
38	Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2020, 73, 1264-1274.	1.5	4
39	Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. <i>Pediatric Rheumatology</i> , 2021, 19, 131.	0.9	3
40	CARRA. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, 531-543.	0.8	3
41	A12: The Role of Serum S100A12 Protein Levels in Disease Flare After Withdrawal of Anti-tumor Necrosis Factor Therapy in Polyarticular Forms of Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, S19-S20.	2.9	2
42	A68: The Role of Serum S100A12 Protein Levels in Maintaining Inactive Disease on Anti-tumor Necrosis Factor Therapy in Polyarticular Forms of Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2014, 66, S99-S100.	2.9	2
43	A34: Seeing the Forest Through the Trees: Predictors of Inflammatory Causes of Joint Pain in New Patients. <i>Arthritis and Rheumatology</i> , 2014, 66, S53-S53.	2.9	2
44	Translating research into practice—implementation recommendations for pediatric rheumatology; Proceedings of the childhood arthritis and rheumatology research alliance 2020 implementation science retreat. <i>Pediatric Rheumatology</i> , 2022, 20, 10.	0.9	2
45	Co-design of an Electronic Dashboard to Support the Coproduction of Care in Pediatric Rheumatic Disease: Human-Centered Design and Usability Testing. <i>Journal of Participatory Medicine</i> , 2022, 14, e34735.	0.7	2
46	Dr. Janow, et al reply. <i>Journal of Rheumatology</i> , 2017, 44, 960.2-960.	1.0	0
47	Pediatric Rheumatology Comes of Age. <i>Rheumatic Disease Clinics of North America</i> , 2021, 47, xvii-xviii.	0.8	0
48	Pediatric Rheumatology Comes of Age: Part II. <i>Rheumatic Disease Clinics of North America</i> , 2022, 48, xix-xx.	0.8	0
49	The importance of rigorous methods in observational comparative effectiveness studies of rare diseases: comment on the article by Ruperto et al. <i>Arthritis and Rheumatology</i> , 2022, 74, 912-913.	2.9	0